Dutasteride: A novel dual inhibitor of 5α-reductase for benign prostatic hyperplasia

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 2, 2005, Pages 311-317

  Djavan, Bob ^a   Milani, Shirin ^b   Fong, Yan Kit ^b  

^a Urologische Universitatsklinik   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Benign prostatic hyperplasia; Efficacy; Prostate volume; Sexual adverse events

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; ISOENZYME; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN;

ANTINEOPLASTIC ACTIVITY; BONE DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; EJACULATION DISORDER; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FATIGUE; GYNECOMASTIA; HORMONE INHIBITION; HUMAN; IMPOTENCE; IN VITRO STUDY; LIBIDO DISORDER; LIVER DYSFUNCTION; LONG TERM CARE; MALAISE; MALE; MALE SEXUAL DYSFUNCTION; ORGAN SIZE; PROSTATE HYPERTROPHY; PROSTATE SURGERY; QUALITY OF LIFE; REVIEW; URINE FLOW RATE; URINE RETENTION;

AZASTEROIDS; ENZYME INHIBITORS; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 14544275477     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.2.311     Document Type: Review

References (23)

1. NAPALKOV P, MAISONNEUVE P, BOYLE P: Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology (1995) 46:41-46.
2. GREENLEE RT, HILL-HARMON MB, MURRAY T, THUN M: Cancer statisitics 2001. CA Cancer J. Clin. (2001) 51:15-37.
3. PETROW V: The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications. Prostate (1986) 9:343-347.
4. BRUCHOVSKY N, RENNIE PS, BATZOLD FH et al.: Kinetic parameters of 5 alpha-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates. J. Clin. Endocrinol. Metab. (1988) 67:806-811.
5. MCCONNELL JD, BRUSKEWITZ R, WALSH P et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy Safety Study Group. N. Engl. J. Med. (1998) 338:557-563.
6. MARBERGER MJ: Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS study group. Urology (1998) 51 677-686.
7. THOMPSON IM, GOODMAN PJ, TANGEN CM et al.: The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. (2003) 349:215-224.
8. BRUCHOVSKY N, SADAR MD, AKAKURA K et al.: Characterization of 5 alpha-reductase gene expression in stroma and epithelium of human prostate. J. Steroid Biochem. Mol. Biol. (1996) 59:397-401.
9. THIGPEN AE, SILVER RI, GUILEYARDO JM et al.: Tissue distribution and ontogeny of steroid 5 alpha-reductase isoenzyme expression. J. Clin. Invest. (1993) 92:903-908.
10. THOMAS LN, DOUGLAS RC, VESSEY JP et al.: 5 alpha-reductase Type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J. Urol. (2003) 170:2019-2023.
11. CLARK RV, HERMANN DJ, GABRIEL H et al.: Effective suppression of dihydrotestosterone (DHT) by GI198745, a novel dual alpha-reductase inhibitor. J. Urol. (1999) 161:268 (Abstract 1037).
12. MCCONNELL JD, WATSON JD, GEORGE FW et al.: Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. (1992) 74:505-510.
13. ROEHRBORN CG, BOYLE P, NICKEL JC et al.: Efficacy and safety of dual inhibitor of 5-alpha-reductase types 1 and 2 (Dutasteride) in men with benign prostatic hyperplasia. Urology (2002) 60 434-441.
14. O'LEARY MP, ROEHRBORN CG, ANDRIOLE G et al.: Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5-alpha-reductase inhibitor. BJU Int. (2003) 92:262-266.
15. DEBRUYNE F, BARKIN J, VAN ERPS P et al.: Efficacy and safety of long-term treatment with 5 alpha-reductase inhibitor of dutasteride in men with symptomatic benign prostatic hyperplasia. Eur. Urol. (2004) 46:488-495.
16. BARKIN J, GUIMARAES M, JACOBI G et al.: Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the 5-alpha-reducatse inhibitor dutasteride. Eur. Urol. (2003) 44:461-466.
17. BALDWIN KC, GINSBERG PC, HARKAWAY RC: Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction. Urol. Int. (2001) 66:840-888.
18. ANDRIOLE GL, KIRBY R: Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur. Urol. (2003) 44:82-88.
19. ANDRIOLE GL, ROEHRBORN C, SCHULMAN C et al.: Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology (2004) 64:537-543.
20. ANDRIOLE GL, HUMPHREY P, RAY P et al.: Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J. Urol. (2004) 172:915-919.
21. ANDRIOLE GL, BOSTWICK D, BRAWLEY O et al.: Chemoprevention of prostate cancer in men at high risk: Rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J. Urol. (2004) 172:1314-1317.
22. SARMA AV, JACOBSEN SJ, GIRMAN CJ et al.: Concomittant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men. J. Urol. (2002) 168 1446-1452.
23. MCCONNELL JD, ROEHRBORN CG, BAUSTITA OM et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. (2003) 349:2387-2398.